A general practice evaluation of pivmecillinam given twice daily as a treatment for acute urinary tract infection.
In a multi-centre study in general practice, 292 female patients with acute urinary tract infection received a 5-day course of pivmecillinam at a dosage of either 200 mg or 400 mg twice-daily. Positive bacteriological cultures were obtained from 64 (31%) of 206 patients for whom bacteriological data was complete, and bacteriological cures were obtained in all 38 patients in the lower dose group and 22 (85%) of the 26 patients in the higher dose group. An equally good clinical response was seen with both treatments and the mean symptom score (maximum possible 15) was reduced from 7.46 to 0.73. Side-effects were reported for 7 (4%) patients in the lower dose group and 11 (10%) patients in the higher dose group. Two patients in each group ceased treatment due to nausea, which was the most frequently reported complaint.
D000293:Adolescent; D000328:Adult; D000560:Amdinocillin / Q000627:therapeutic use*; D000561:Amdinocillin Pivoxil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001437:Bacteriuria / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000561:Amdinocillin Pivoxil; D000560:Amdinocillin